Literature DB >> 31145081

Assessing the psychological burden of patients with hidradenitis suppurativa.

Verena G Frings1, Boris Bauer1, Manuel Glöditzsch1, Matthias Goebeler1, Dagmar Presser1.   

Abstract

Hidradenitis suppurativa (HS) causes a significantly compromised quality of life. Assessment of the psychological burden of HS is crucial for evidence-based allocation of resources. We examined methods to easily assess the psychological burden in HS patients. A total of 110 HS patients were assessed with respect to sociodemographic data, Hurley scale, and modified Sartorius score. Patients were asked to provide information on time of first diagnosis, previous therapies, surgical intervention, and pre-existing conditions. Distributed questionnaires were the Dermatology Life Quality Index (DLQI) and the Skindex-29, the Visual Analogue Scale (VAS) for pain, and the German version of the Hospital Anxiety and Depression Scale (HADS-D) for evaluation of anxiety (HADS-D/A) and depression (HADS-D/D). Of the 110 patients with HS (mean age: 38 ± 12 years; range: 18 to 75), 61 were female and 49 were male. We found a statistically significant correlation between HADS-D/A and VAS (p = 0.009), between Skindex-29 and Sartorius score (symptoms: p = 0.024; emotions: p = 0.019; functional status: p = 0.002), as well as between Skindex-29 and VAS (symptoms: p = 0.000; emotions: p = 0.001; functional status: p = 0.000). Additionally, VAS correlated significantly with DLQI (p = 0.000) and body mass index with Sartorius score (p = 0.038). Our study shows that HS patients experience a high level of psychological distress. Interestingly, a clear correlation between psychological burden and HS patients was inferred by the VAS for pain. HS patients require active management for their physical as well as psychological health.

Entities:  

Keywords:  acne inversa; burden of disease; comorbidities; depression; hidradenitis suppurativa; patient-reported outcomes

Mesh:

Year:  2019        PMID: 31145081     DOI: 10.1684/ejd.2019.3552

Source DB:  PubMed          Journal:  Eur J Dermatol        ISSN: 1167-1122            Impact factor:   3.328


  7 in total

Review 1.  [Epidemiology, patient quality of life, and treatment costs of hidradenitis suppurativa/acne inversa].

Authors:  N Kirsten; V Frings; G D Nikolakis; D Presser; M Goebeler; C C Zouboulis; M Augustin
Journal:  Hautarzt       Date:  2021-07-05       Impact factor: 0.751

Review 2.  [Hidradenitis suppurativa/acne inversa in daily practice].

Authors:  H Kurzen; K Fritz; A Altenburg
Journal:  Hautarzt       Date:  2021-07-05       Impact factor: 0.751

3.  Features Associated With Quality of Life Impairment in Hidradenitis Suppurativa Patients.

Authors:  Sylke Schneider-Burrus; Athanasia Tsaousi; Sebastian Barbus; Johannes Huss-Marp; Katrin Witte; Kerstin Wolk; Björn Fritz; Robert Sabat
Journal:  Front Med (Lausanne)       Date:  2021-04-27

4.  Quality-of-Life Impairment among Patients with Hidradenitis Suppurativa: A Cross-Sectional Study of 1795 Patients.

Authors:  Piotr K Krajewski; Łukasz Matusiak; Esther von Stebut; Michael Schultheis; Uwe Kirschner; Georgios Nikolakis; Jacek C Szepietowski
Journal:  Life (Basel)       Date:  2021-01-08

5.  Quality of Life of Patients With Hidradenitis Suppurativa in Jeddah, Saudi Arabia.

Authors:  Awadh M Alamri; Abeer A Alzahrani; Anan M Aldakhil; Heba E Alharbi; Farah A Yahya
Journal:  Cureus       Date:  2021-12-07

6.  Correlation between Depression, Quality of Life and Clinical Severity in Patients with Hidradenitis Suppurativa.

Authors:  Francesca Sampogna; Luca Fania; Simona Mastroeni; Roberta Fusari; Monica Napolitano; Davide Ciccone; Cinzia Mazzanti; Sabatino Pallotta; Annarita Panebianco; Damiano Abeni
Journal:  Acta Derm Venereol       Date:  2020-11-12       Impact factor: 3.875

7.  Economic analysis of the costs associated with Hidradenitis suppurativa at a German University Hospital.

Authors:  Verena Gerlinde Frings; Oliver Schöffski; Matthias Goebeler; Dagmar Presser
Journal:  PLoS One       Date:  2021-08-04       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.